The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...
Pfizer ( PFE +0.26%) and Eli Lilly ( LLY +1.80%) are two prominent names in healthcare that have focused on innovation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results